ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration.

MLA

Hirose, Takuo, et al. “ATP6AP2 Variant Impairs CNS Development and Neuronal Survival to Cause Fulminant Neurodegeneration.” The Journal of Clinical Investigation, vol. 129, no. 5, Apr. 2019, pp. 2145–62. EBSCOhost, https://doi.org/10.1172/JCI79990.

APA

Hirose, T., Cabrera-Socorro, A., Chitayat, D., Lemonnier, T., Féraud, O., Cifuentes-Diaz, C., Gervasi, N., Mombereau, C., Ghosh, T., Stoica, L., Bacha, J. d’Arc A., Yamada, H., Lauterbach, M. A., Guillon, M., Kaneko, K., Norris, J. W., Siriwardena, K., Blasér, S., Teillon, J., … Groszer, M. (2019). ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration. The Journal of Clinical Investigation, 129(5), 2145–2162. https://doi.org/10.1172/JCI79990

Chicago

Hirose, Takuo, Alfredo Cabrera-Socorro, David Chitayat, Thomas Lemonnier, Olivier Féraud, Carmen Cifuentes-Diaz, Nicolas Gervasi, et al. 2019. “ATP6AP2 Variant Impairs CNS Development and Neuronal Survival to Cause Fulminant Neurodegeneration.” The Journal of Clinical Investigation 129 (5): 2145–62. doi:10.1172/JCI79990.